Homepage Archives - Geneseeq Technology Inc. | A Precision Oncology Company

August 11, 2026

Geneseeq Expands PanTRKare™ with a Third NMPA-Approved CDx Application for VELMARTO® (Eratrectinib)

July 14, 2026

Geneseeq Canada Named First Genomic Testing Partner in UHN’s SHERLOCK Study

November 10, 2025

Geneseeq Receives NMPA Approval for PanTRKare™ – China’s First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions

September 29, 2025

Geneseeq Validates Cell-free DNA Blood Test for Early Detection of Pancreatic Cancer in a Prospective Study

September 2, 2025

GeneseeqPrime® Gains FDA 510(k) Clearance

May 28, 2025

Geneseeq’s Breakthrough Cancer Detection Blood Test Published in Nature Medicine

May 21, 2025

Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025

May 7, 2025

Geneseeq Unveils Groundbreaking Blood Test for Early Detection of Pancreatic Cancer

December 3, 2024

GENESEEQ’S NGS LIQUID BIOPSY KIT MARKS THE FIRST TO ENTER NMPA’S SPECIAL REVIEW AND APPROVAL OF INNOVATIVE MEDICAL DEVICE

July 3, 2024

Geneseeq partners with Jiangsu Vcare PharmaTech to develop a CDx for NTRK inhibitor in China.